Moving towards a strategy to accelerate cervical cancer elimination in a high-burden city-Lessons learned from the Amazon city of Manaus, Brazil
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
TORRES, Katia Luz
RONDON, Heidy Halanna de Melo Farah
MARTINS, Sandro
RIBEIRO, Ana
RAIOL, Taina
MARQUES, Carla Pintas
CORREA, Flavia
MIGOWSKI, Arn
MINUZZI-SOUZA, Thais Tamara Castro e
Citação
PLOS ONE, v.16, n.10, article ID e0258539, 15p, 2021
Resumo
The World Health Organization Call to Eliminate Cervical Cancer resonates in cities like Manaus, Brazil, where the burden is among the world's highest. Manaus has offered free cytology-based screening since 1990 and HPV immunization since 2013, but the public system is constrained by many challenges and performance is not well-defined. We obtained cervical cancer prevention activities within Manaus public health records for 2019 to evaluate immunization and screening coverage, screening by region and neighborhood, and the annual Pink October screening campaign. We estimated that among girls and boys age 14-18, 85.9% and 64.9% had 1+ doses of HPV vaccine, higher than rates for age 9-13 (73.4% and 43.3%, respectively). Of the 90,209 cytology tests performed, 24.9% were outside the target age and the remaining 72,230 corresponded to 40.1% of the target population (one-third of women age 25-64). The East zone had highest screening coverage (49.1%), highest high-grade cytology rate (2.5%) and lowest estimated cancers (38.1/100,000) compared with the South zone (32.9%, 1.8% and 48.5/100,000, respectively). Largest neighborhoods had fewer per capita screening locations, resulting in lower coverage. During October, some clinics successfully achieved higher screening volumes and high-grade cytology rates (up to 15.4%). Although we found evidence of some follow-up within 10 months post-screening for 51/70 women (72.9%) with high-grade or worse cytology, only 18 had complete work-up confirmed. Manaus has successfully initiated HPV vaccination, forecasting substantial cervical cancer reductions by 2050. With concerted efforts during campaigns, some clinics improved screening coverage and reached high-risk women. Screening campaigns in community locations in high-risk neighborhoods using self-collected HPV testing can achieve widespread coverage. Simplifying triage and treatment with fewer visits closer to communities would greatly improve follow-up and program effectiveness. Achieving WHO Cervical Cancer Elimination goals in high-burden cities will require major reforms for screening and simpler follow-up and treatment.
Palavras-chave
Referências
- Aharon D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169327
- Alves, 2019, MEDICINA, V52, P110
- [Anonymous], 2020, MINISTERIO SAUDE API
- Arbyn M, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4823
- Austad K, 2018, J GLOB ONCOL, V4, DOI 10.1200/JGO.17.00228
- Baandrup L, 2021, CLIN INFECT DIS, V73, pE3220, DOI 10.1093/cid/ciaa1067
- Baker ML, 2015, REV PANAM SALUD PUBL, V38, P163
- Barrett BW, 2020, JCO GLOB ONCOL, V6, P1237, DOI 10.1200/GO.20.00096
- Batmunkh T, 2020, VACCINE, V38, P4316, DOI 10.1016/j.vaccine.2020.04.041
- BOUVARD V, 2009, LANCET ONCOL, V10, P321, DOI [10.1016/s1470-2045(09)70096-8, DOI 10.1016/S1470-2045(09)70096-8]
- Buss LF, 2021, INT J GYNECOL OBSTET, V152, P72, DOI 10.1002/ijgo.13362
- Campos NG, 2017, HEALTH POLICY PLANN, V32, P956, DOI 10.1093/heapol/czw182
- Clarke MA, 2018, CLIN CANCER RES, V24, P2194, DOI 10.1158/1078-0432.CCR-17-3251
- Desai KT, 2020, INFECT AGENTS CANCER, V15, DOI 10.1186/s13027-020-00324-5
- Dillner J, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1754
- Eggleston KS, 2007, J WOMENS HEALTH, V16, P311, DOI 10.1089/jwh.2006.0161
- FAISALCURY A, 2020, BMC PUBLIC HEALTH, V20, P1, DOI 10.1186/S12889-019-7969-5
- Gibson EG, 2019, WOMEN HEALTH ISS, V29, P38, DOI 10.1016/j.whi.2018.09.006
- Gilca V, 2018, VACCINE, V36, P7017, DOI 10.1016/j.vaccine.2018.09.057
- INCA, EST 2020 CANC INC BR
- INCA, 2016, MAN GEST QUAL LAB CI
- INCA, 2019, PAR TECN RASTR CANC
- INCA, 2016, DIR BRAS RASTR CANC
- Koliopoulos G, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008587.pub2
- Kreimer AR, 2020, JNCI-J NATL CANCER I, V112, DOI 10.1093/jnci/djaa011
- Lemp JM, 2020, JAMA-J AM MED ASSOC, V324, P1532, DOI 10.1001/jama.2020.16244
- Mayrand M, 2007, NEW ENGL J MED, V357, P1579, DOI 10.1056/NEJMoa071430
- Moura LdL., COB VAC PAP HUM HPV
- MS. Ministerio da Saude, REL REC COM NAC INC
- Nicolau AIO, 2017, REV LAT-AM ENFERM, V25, DOI 10.1590/1518-8345.1845.2948
- Soares MBO, 2016, REV BRAS ENFERM, V69, P381, DOI 10.1590/0034-7167.2016690226i
- PAHO, PAN AM HLTH ORG METH
- Paul P, 2014, VACCINE, V32, P320, DOI 10.1016/j.vaccine.2013.11.070
- PERMAN S, 2017, BMC PUBLIC HEALTH, V17, P1, DOI 10.1186/S12889-016-3954-4
- Pilleron S, 2020, INT J CANCER, V147, P1638, DOI 10.1002/ijc.32956
- Polman NJ, 2019, LANCET ONCOL, V20, P229, DOI 10.1016/S1470-2045(18)30763-0
- Ribeiro CM, 2019, CAD SAUDE PUBLICA, V35, DOI [10.1590/0102-311X00183118, 10.1590/0102-311x00183118]
- Rodriguez AC, 2017, INT J CANCER, V140, P1926, DOI 10.1002/ijc.30614
- Primo WQSP, 2021, REV BRAS GINECOL OBS, V43, P1, DOI 10.1055/s-0041-1722939
- Schechtman NP, 2012, REV BRASILEIRA EDUCA, V36, P155
- Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
- Schiffman M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.86
- Schiffman M, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.530
- SEMSA, 2018, PLAN MUN SAUD MAN 20, P108
- Smith M, 2019, PUBLIC HEALTH RES PR, V29, DOI 10.17061/phrp2921914
- Spence AR, 2007, PREV MED, V45, P93, DOI 10.1016/j.ypmed.2007.06.007
- Torres KL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201262
- Wentzensen N, 2021, PREV MED, V144, DOI 10.1016/j.ypmed.2021.106439
- WHO, 2019, GUID US THERM ABL CE